Pfizer is always open to Australia though they've got toes dipped in a few Aus-Bio's through either/or patnerships & stock holdings.
I guess the most likely candidate to look for would be the big pharma that is most highly focussed on the relevant disease area. Or of course threatened by any new potentially superior treatment.
End of year will tell the story make or break - hopefully not a Teva outcome all over again.
ANP Price at posting:
29.0¢ Sentiment: None Disclosure: Held
